IT Leaders May Underestimate the Risk of Shadow SaaS, Finds New Snow Software Survey
17.11.2022 17:00:00 EET | Business Wire | Press release
Snow Software, the global leader in technology intelligence, today unveiled new data highlighting the challenges facing IT leaders due to expanded software as a service (SaaS) usage. While a huge majority of IT leaders (96%) indicated they were ‘confident or very confident’ in their organization’s SaaS security measures, the top challenge for leaders managing SaaS was ‘employees adding new SaaS applications without notifying IT,’ suggesting that leaders may underestimate the importance of visibility in security.
According to IDC, SaaS is the top source for cloud spend in 2022, accounting for $177.8 billion of the market. In the new Snow survey examining the state of SaaS management, which surveyed 1,000 IT leaders from large organizations of 500+ employees in the United States and United Kingdom, 44% said ‘employees adding new SaaS applications without notifying IT’ is their top challenge to managing SaaS applications at their organization, closely followed by managing SaaS security (42%). When asked why these issues were so challenging, IT leaders indicated the impact to other IT programs (47%), organizational dynamics (38%), lack of time and resources (37%) and lack of visibility (36%).
“Post-pandemic IT teams are seeing a large increase in SaaS applications procured without the knowledge of IT,” said Becky Trevino, Executive Vice President of Products at Snow. “Amid increasing cybersecurity risks and mounting pressure to cut costs, IT leaders realize they need to better govern unknown and unsanctioned SaaS usage. CIOs are ultimately responsible for the security and management of SaaS applications regardless of where they are procured, and to do this effectively IT needs complete visibility into what it is they need to secure.”
Views on budget and security ownership depends on your leadership level
Cybersecurity is a major focus for IT decision-makers right now, particularly as business leaders navigate market uncertainty and plan 2023 budgets in anticipation of a recession. However, ownership is not clear among IT leaders, which can put organizations at risk for elevated costs and gaps in security.
- IT leaders ranked ‘managing the security of SaaS applications’ as the #1 most important issue to managing SaaS applications at their organization, followed by ‘identifying usage of all SaaS applications within our organization.’
- Ninety-six percent of those surveyed reported feeling ‘confident’ or ‘very confident’ in their organization’s SaaS security measures.
- According to the survey, SaaS purchasing power and IT/security responsibility rests firmly within two groups: CIOs/IT leadership and IT asset management (ITAM) or software asset management (SAM) teams.
- Senior leaders (41% of vice presidents, 45% of sr. vice presidents and 52% of C-level executives) look to the CIO and/or IT leadership to take responsibility for SaaS purchasing and security issues over other departments and roles, while more mid-level management (50% of managers and 44% of directors) put the onus of SaaS management and security on peers within ITAM/SAM.
- Forty-eight percent of IT leaders surveyed said that if budget, resources and time were not a factor, they’d like to pivot all SaaS application spending to IT to address SaaS sprawl.
Economic uncertainty is elevating cost concerns among IT leaders – though it’s not the top priority
Market conditions are driving increased scrutiny across all areas of cost in most organizations and optimizing spend while eliminating waste is an ongoing priority for IT teams. However, of those surveyed, IT leaders are currently more focused on cybersecurity of SaaS applications than costs.
- Despite continued uncertainty across the global markets, reining in the total cost of SaaS applications was ranked 5th on respondents’ priorities.
- If global uncertainty persists, more than three quarters of all respondents (77%) believe IT spend will decrease by as much as 50% to 75%.
- If IT spending decreases, IT leaders believe that the two core areas impacted will be IT staffing (20%) and strategic IT initiatives or programs (19%).
For more information about Snow’s latest survey, please visit: https://www.snowsoftware.com/blog/survey-anxiety-over-saas-security-plagues-it-leaders/
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005232/en/
Contact information
Rachel Austin
Snow Software
press@snowsoftware.com
Taylor Donatell
PAN Communications
snow@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
